Medicinal cannabis company AusCann Group (ASX:AC8) has confirmed that Mr Ido Kanyon has commenced as the company's CEO.
The company announced Mr Kanyon’s appointment in February.
He is an experienced global pharmaceutical executive with more than 15 years experience across the life-science value chain.
Mr Kanyon's experience covers a range of healthcare technologies and commercial strategies, from capsules and inhalers to innovative biologics and digital health solutions.
"Mr Kanyon is highly regarded in the pharmaceutical industry and his background in product development and commercialisation is ideally suited to lead AusCann’s next phase of growth as a pharmaceutical development, sales and marketing business," said the company in a statement.
“I am excited to have formally joined the team at AusCann. I see tremendous opportunity for AusCann to lead in the delivery of cannabisbased pharmaceutical solutions that are endorsed by physicians and address the needs of patients who are suffering from inadequately treated medical conditions," said Mr Kanyon.
“The company has built a strong platform on which we will continue to grow. We have begun a comprehensive review of our strategic priorities that will help us tailor our operating plans to ensure we deliver the positive healthcare outcomes and shareholder returns we are seeking.”
Mr Kanyon will relocate to Perth from the US. Interim CEO, Dr Paul MacLeman, will now revert back to his role as an executive director of the company.